Economic evaluation of prostate cancer risk assessment methods: A cost‐effectiveness analysis using population data

BACKGROUND: The current prostate cancer (PCa) screening standard of care (SOC) leads to unnecessary biopsies and overtreatment because decisions are guided by prostate‐specific antigen (PSA) levels, which have low specificity in the gray zone (3–10 ng/mL). New risk assessment tools (RATs) aim to imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Tima, Guh, Daphne P., Tam, Alexander C. T., Pataky, Reka E., Black, Peter C., So, Alan, Lynd, Larry D., Zhang, Wei, Conklin, Annalijn I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587968/
https://www.ncbi.nlm.nih.gov/pubmed/37740609
http://dx.doi.org/10.1002/cam4.6587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587968/
https://www.ncbi.nlm.nih.gov/pubmed/37740609
http://dx.doi.org/10.1002/cam4.6587

Ejemplares similares